Jeffrey del Carmen - 08 Dec 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Del Carmen
Issuer symbol
CPRX
Transactions as of
08 Dec 2025
Net transactions value
$0
Form type
4
Filing time
10 Dec 2025, 17:00:35 UTC
Previous filing
28 Nov 2025
Next filing
30 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Del Carmen Jeffrey Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Jeffrey Del Carmen 10 Dec 2025 0001816477

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +8,039 +203% 12,001 08 Dec 2025 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Tax liability -2,492 -21% 9,509 08 Dec 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -8,039 -0.76% $0.000000 1,045,513 08 Dec 2025 Common Stock 8,039 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
F3 Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025, and 1/3rd on December 8, 2026.
F4 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on December 8, 2025.